Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 3/20 | 0.53 |
| ▸ | CCR1 | P32246 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233756 | 0.90 | SIGMAR1 (0.70) | OPRL1SIGMAR1POLBDRD2KCNA3 | |
| SCHEMBL7243212 | 0.84 | OPRM1 (0.52) | OPRL1SIGMAR1OPRM1MEN1KMT2A | |
| SCHEMBL24489451 | 0.83 | OPRL1 (0.65) | OPRL1SIGMAR1POLBDRD2KCNA3 | |
| SCHEMBL2059079 | 0.83 | OPRL1 (0.68) | OPRL1SIGMAR1POLBDRD2KCNA3 | |
| SCHEMBL8097585 | 0.81 | SIGMAR1 (0.82) | OPRL1SIGMAR1POLBDRD2KCNA3 | |
| SCHEMBL9370237 | 0.81 | SIGMAR1 (0.72) | OPRL1SIGMAR1POLBDRD2KCNA3 | |
| SCHEMBL11778752 | 0.80 | SIGMAR1 (0.70) | OPRL1SIGMAR1POLBDRD2OPRM1 | |
| SCHEMBL11062805 | 0.80 | SIGMAR1 (0.70) | OPRL1SIGMAR1POLBDRD2OPRM1 | |
| SCHEMBL7106817 | 0.79 | OPRL1 (0.60) | OPRL1SIGMAR1POLBDRD2KCNA3 | |
| SCHEMBL8741953 | 0.79 | OPRL1 (0.60) | OPRL1SIGMAR1POLBDRD2KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| EP-0178947-B1 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4812451-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-14 | — | — | US | disclosed |
| US-4812452-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-14 | — | — | US | disclosed |
| US-4810703-A | ANTIARRHYTHMIA | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| US-4642348-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-02-10 | — | — | US | disclosed |
| US-4594343-A | FOR DEEP FAT FRYING VAT OIL; REMOVING CONTAMINANTS; RESTAURANTS | A.H. ROBINS COMPANY, INCORPORATED, A DE CORP. | 1986-06-10 | — | — | US | disclosed |
| US-4593102-A | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0178947-A2 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | disclosed |
| US-4558155-A | N-(Aryloxyalkyl)-N'-(aminoalkyl)thioureas | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0160436-A2 | N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-11-06 | — | — | EP | disclosed |
| US-4500529-A | ANTIARRHYTHMIA AGENT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-02-19 | — | — | US | disclosed |
| US-4006232-A | Therapeutic method of treating cardiac arrhythmias utilizing 3-substituted diphenylhydantoins | MILES LABORATORIES, INC. (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | OPRL1 4144/4885SIGMAR1 4605/4885POLB 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.